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Background: A typical antipsychotics for neuropsychiatric symptoms in dementia have
been tested in much larger trials than the older conventional drugs. The advantage of
larger sample sizes is that negative findings become less likely and the effect estimates
more precise. However, as sample sizes increase, the trials also get more expensive and
time consuming while exposing more patients to drugs with unknown safety profiles.
Moreover, a large sample size might yield a statistically significant effect that is not
necessarily clinically relevant.
Objective: To assess (1) the variation in sample size and sample size calculations of
antipsychotic trials in dementia, (2) the size of reported treatment effects and related
statistical significance, and (3) general study characteristics that might be related to
sample size.
Study Design and Setting:We performed a meta-epidemiological study of randomized
trials that tested antipsychotics for neuropsychiatric symptoms in dementia. The trials
compared conventional or atypical antipsychotics with placebo or another antipsychotic.
Two reviewers independently extracted sample size, sample size calculations, reported
treatment effects with p-values, and general study characteristics (drug type, trial duration,
type of funding). We calculated a reference sample size of 83 and 433 per study group for
the placebo-controlled and head-to-head trials respectively.
Results: We identified 33 placebo-controlled trials, and 18 head-to-head trials. Only 14
(42%) and 2 (11%), respectively, reported a sample size calculation. The average sample
size per arm was 34 (range 6–179) in placebo-controlled trials testing conventional drugs,
107 (8–237) in such trials testing atypical drugs, and 104 (95–115) in such trials testing
both drug types; it was 31 (10–88) in head-to-head trials. Thirteen out of 18 trials with
sample sizes larger than required (72%) reported a statistically significant treatment effect,
of which two (15%) were clinically relevant. None of the head-to-head trials reported a
statistically significant treatment effect, even though some suggested non-inferiority. In
placebo-controlled trials of atypical drugs, longer trial duration (>6 weeks) and commercial
funding were associated with higher sample size.in.org February 2020 | Volume 10 | Article 17011
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Frontiers in Pharmacology | www.frontiersConclusion: Sample size calculations were poorly reported in antipsychotic trials for
dementia. Placebo-controlled trials of atypical antipsychotics showed large sample size
fallacy while head-to-head trials were massively underpowered.Keywords: sample size, power, antipsychotics, dementia, placebo-controlled trials, head-to-head trials, meta-
epidemiological studyINTRODUCTION
Over the years the sample sizes of antipsychotic trials in
dementia have increased from as low as 18 in the 1960s to as
high as 652 in the 1990s (Schneider et al., 2005; Cox Grad, 2009;
Hulshof et al., 2015). The increase in sample sizes is generally
viewed as a favorable development. Larger sample sizes provide
more power to identify a treatment effect that is really present. In
addition, the effect is estimated more precisely (smaller
confidence intervals). Larger trials are also a natural
consequence of head-to-head trials because the difference
between two active drugs is generally expected to be small, and
therefore, the required sample size needs to be relatively high.
However, larger sample sizes also make trials expensive and
time consuming (Cox Grad, 2009). This can be barrier for non-
commercial investigators to perform a trial. Moreover, it can be
ethically questionable to ask more patients to participate,
especially when the safety of the tested drug has not yet been
established (Schipper and Weyzig, 2008). Another disadvantage
of (very) large sample size is that a difference in outcomes
between the groups will become (very) statistically significant,
no matter how small or clinically meaningless it is (Sullivan and
Feinn, 2012). If such results are nevertheless interpreted as
clinically relevant, the ‘large sample size fallacy’ occurs
(Lantz, 2013).
Sample size calculations for trials are based on four
parameters if the response rate is the outcome. These are
alpha, beta, the expected response rate in the active treatment
groups, and the expected response rate in the comparison group
(e.g. placebo) (Noordzij et al., 2010). Alpha is the probability of
identifying a treatment effect that is not really present, which is
usually set at 5%. Beta is the risk of not identifying a treatment
effect that is really present, and is usually set at 20%. Sample size
calculations for trials with continuous outcomes, such as the
reduction of neuropsychiatric symptoms (NPS), are based on
alpha, beta, the expected (difference between) means in the active
and comparison group, and the population variance around the
mean. Furthermore, the expected number of participants
dropping out should be taken into account when determining
the final target sample size of a trial.
A different expected treatment effect might explain why the
sample sizes of antipsychotic trials increased over time. Perhaps,
atypical antipsychotics were expected to be less effective than
conventional antipsychotics, even before it was shown in
systematic reviews that they did not affect psychotic symptoms
compared to placebo (Schneider et al., 2006; Smeets et al., 2018).
Alternatively, drop-out could have increased because recent trials
lasted longer and participants have become more assertive.in.org 2On the other hand, general study characteristics, which are
not directly related to sample size calculation might have
contributed to the increase in trial sample sizes over the years.
Large sample size is generally considered a sign of high trial
quality, and this increases the probability of publication and
citation (Dickersin et al., 1992). In addition, pharmaceutical
companies will have more resources to fund larger trials than
non-commercial organizations. Therefore, the aim of this meta-
epidemiological study was to assess (1) the variation in sample
size and sample size calculations of antipsychotic trials in
dementia, (2) the size of the reported treatment effects and
related statistical significance, and (3) general study
characteristics that might be related to sample size.METHODS
Search Strategy
Two reviewers (TAH, HJL) used a list of conventional and
atypical antipsychotics from the websites of the World Health
Organization, Food and Drug Administration, and Wikipedia to
search the literature (US Food and Drug Administration, 2013;
World Health Organization, 2013; Wikipedia, 2015). First, we
first searched for studies in the electronic databases PubMed,
CINAHL, EMBASE, and Cochrane library with the string
‘generic name of atypical/conventional antipsychotic’ and trial
and dementia (see online supplement). We restricted the
position of the drug name to title and abstract. Subsequently,
we manually searched the references of published systematic
reviews, which were identified with the same electronic
databases. Titles and abstracts of potentially eligible studies
were retrieved from PubMed. In addition, we sought trials in
trial registration websites with the abovementioned search terms
if possible; otherwise we used only the term dementia. These
three searches were last re-run in June 2019. Finally, we had used
the databases of the Dutch Medicines Evaluation Board and the
FDA to find unpublished trials as part of a previous search
performed in 2015 (Hulshof et al., 2019).
Study Selection
We screened the title and abstract of the hits. Full texts of
potentially eligible published studies and online protocols for
unpublished studies were retrieved. Two reviewers used the full
texts to determine definitive eligibility (TAH, HJL). The selected
trials had to have been randomized and double-blind. They
should have tested the efficacy of antipsychotics on NPSs in
persons diagnosed with Alzheimer or vascular dementia. The
trial had to compare conventional or atypical antipsychotics withFebruary 2020 | Volume 10 | Article 1701
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excluded studies with multiple drugs in a single intervention
arm, studies that were stopped early and thus did not reach the
targeted sample size, and studies with a cross-over design as
other than standard sample size calculations need to be applied
for this design. There were no restrictions with respect to
publication date, language, and duration of the study.
Data Extraction
Two reviewers (TAH or SIMJ and HJL) independently extracted
the following general study characteristics besides the sample size
from the included studies: placebo-controlled or head-to-head
trial, type of dementia (Alzheimer’s disease, vascular dementia,
mixed, unspecified), type of NPS (agitation, psychosis, diverse),
setting (nursing home, hospital, outpatient clinic), active drug
tested (conventional, atypical, or both), trial duration, type of
funding (not-for-profit or commercial), and whether a sample
size calculation was reported.
If the sample size calculation was reported, we extracted the
input for sample size calculations: alpha, beta, expected
treatment effects in the comparison groups (response rate, or
mean symptom reduction with population variance at endpoint),
and the expected drop-out rates. For trials that had been
published in an abstract or online trial registration only, this
data-extraction was considered inapplicable.
In addition, we extracted the reported treatment effects and
related statistical significance. The primary outcome of trials that
test antipsychotics for NPS in dementia is most often the
difference in response rate or difference in reduction of target
symptoms between the treatment groups. We extracted both for
each trial with the related p-value. For the response rate, we
extracted the number of patients with a clinically relevant
improvement as defined by the authors. For reduction in
symptoms, we extracted the difference in mean change from
baseline to endpoint as measured with a symptom scale, such as
the Cohen-Mansfield Agitation Inventory (CMAI) for agitation
and Neuropsychiatric Inventory-Nursing Home (NPI-NH) for
mixed symptoms. Initially, we also set out to extract standard
deviations to calculate standardized mean differences, so that we
could compare trial results. However, as many SDs turned out to
be missing, we decided to extract the mean on the symptom scale
at baseline as a reference instead (see data-analysis).
The primary source of extracted data was the published main
results article. If that was not available, then conference abstracts
or online published results were used. We received the individual
patient data of two trials (Schneider et al., 2006; Paleacu et al.,
2008), and additional meta-data of two others for use in another
study (De Deyn et al., 1999; De Deyn et al., 2005; Hulshof
et al., 2019).
Data Analyses
First, we described the variation in sample sizes for the different
types of trials by plotting the mean number of participants per
comparison group against the publication year of the trial. We
present these data for the conventional and atypical placebo-
controlled trials and head-to head trials separately.Frontiers in Pharmacology | www.frontiersin.org 3To assess the adequacy of the reported sample sizes, we
calculated reference sample sizes for trials with the response
rate as outcome. For the placebo-controlled trials, we used an
alpha of 0.05, beta of 0.20, a treatment response rate in the
antipsychotic group of 55% and in the placebo group of 30%, and
an expected drop-out of 30% (Brant, 2016). A treatment effect of
25% (NNT = 4) and drop-out rate of 30% is in line with previous
literature and the reported response rates in antipsychotic trials
in dementia (Schneider et al., 2006; Jeste et al., 2008; Drouillard
et al., 2013). We used a conservative drop-out rate of 30% (it was
26% on average in the included trials), so that the reference
sample size would not be an underestimation. The required
sample size per study group was 58 without loss to drop-out, and
83 with loss.
For the head-to-head trials (no placebo group), we used a
treatment effect of 55% for the drug of interest and 45% for the
control antipsychotic drug, because a 10% difference seems the
upper limit of no difference. The expected drop-out rate was set
at 10%, which is in line with the average drop-out rate in the
included head-to-head trials. The required sample size was 389
per group without loss, and 433 with loss. We used the ssi
command in Stata version 15.0 to calculate the reference sample
sizes (StataCorp., 2017).
To calculate reference sample sizes based on the outcome
mean symptom reduction, the minimal clinically important
difference (MCID) is required. However, the MCID is not
known for most symptom scales used in this field (Shabbir and
Sanders, 2014). The exception is the NPI, which was found to
have an MCID of at least 8.0 (Howard et al., 2011; Zuidema et al.,
2011). Nine of the included placebo-controlled trials in our study
used this instrument, and we used the reported data to check our
calculated reference sample size based on response rates. The
reported mean reduction in symptoms was 19 (SD 14) for the
placebo group (see Supplementary Table 1), and hence,
assuming an MCID of 8.0, 27 (SD 16) for the antipsychotic
group. We calculated a required sample size of 80 based on these
data, and this finding confirms the reference sample size of 83
based on response rates. In addition, the MCID of 8.0 reflects an
SMD of 0.500 given the SD of 16 reported in the included trials.
This is in line with the lower limit for a visible (medium)
treatment effect suggested by Cohen (2007).
The next step was to assess whether studies with larger sample
size reported statistically significant treatment effects that were
not clinically relevant (difference in response rate <25%;
difference in symptom reduction < MCID or SMD <0.5),
which would suggest the presence of large sample size fallacy.
Treatment effects in terms of reported response rates can be
compared between trials with varying sample sizes. However, it
was not possible to use MCIDs or SMDs to compare reported
reductions in symptoms across different symptoms scales.
Therefore, we calculated the relative symptom reduction as the
ratio of the difference in symptom reduction between the study
groups relative to the baseline mean in the groups. This approach
has been used before (Smith et al., 1974). Moreover, the MCID of
8.0 on the NPI and a mean baseline of 39 (see Supplementary
Table 1) would translate into a relative symptom reduction ofFebruary 2020 | Volume 10 | Article 1701
Hulshof et al. Sample Size in Antipsychotics Trials21%. Hence, a relative symptom reduction of > = 20%
seems appropriate.
Finally, we analyzed the association between other general
study characteristics and mean sample size per group. The
characteristics were type of drug tested (category: conventional,
atypical, or both), trial duration (< = 6 weeks, > 6 weeks), and
type of funding (non-for-profit, commercial). We calculated
mean sample sizes of comparison groups per category, and
used the two-sample t-test to determine whether the means
differed between the first (reference) category and other
categories. The analyses were performed for the placebo-
controlled and head-to-head trials separately. All analyses were
carried out with Stata version 15.0 (StataCorp., 2017).RESULTS
Our search yielded 2,768 potentially relevant hits (Figure 1). We
obtained the reports of 92 studies for full text review. We
considered 57 studies eligible, but 6 had no useable data at the
time of assessment. Hence, we used 51 studies in the current study
(Hamilton and Bennet, 1962; Sugerman et al., 1964; Smith et al.,
1974; Rada and Kellner, 1976; Rosen, 1979; Vergara et al., 1980;Frontiers in Pharmacology | www.frontiersin.org 4Götestam et al., 1981; Barnes et al., 1982; Petrie et al., 1982;
Spagnolo et al., 1983; Morris and Rickels, 1984; Stotsky, 1984;
Ather et al., 1986; Lovett et al., 1987; Carlyle et al., 1993; Finkel
et al., 1995; Auer et al., 1996; Auchus and Cheryl Bissey-Black,
1997; Devanand et al., 1998; De Deyn et al., 1999; Katz et al., 1999;
Allain et al., 2000; Street et al., 2000; Howanitz and Wisotzek,
2001; Herz et al., 2002; Pollock et al., 2002; Brodaty et al., 2003;
Fontaine et al., 2003; De Deyn et al., 2004; Garerl et al., 2004;
Mulsant et al., 2004; Sheng, 2004; Sun et al., 2004; Ballard et al.,
2005; De Deyn et al., 2005; Deberdt et al., 2005; Verhey et al., 2006;
Tariot et al., 2006; Mintzer et al., 2007; Rainer et al., 2007; Zhong
et al., 2007; Paleacu et al., 2008; Streim et al., 2008; Teri et al.,
2000). Online or other clinical trial reports of the following studies
were used: NCT00287742, NCT01862640, NCT01922258,
NCT02992132, ZIP-128-105, RIS-BEL-14, RIS-INT-83.
Table 1 shows the general study characteristics. Eleven trials
compared conventional antipsychotics to placebo and 19 trials
atypical antipsychotics to placebo. Six of the latter 19 trials tested
multiple doses of one atypical drug, so they had more than one
drug group (range 2–4). Three placebo-controlled trials tested
both conventional and atypical antipsychotics. Eighteen trials
compared an antipsychotic drug with another antipsychotic
drug. The studies were performed in outpatients, nursingFIGURE 1 | Flow diagram of literature search and study selection.February 2020 | Volume 10 | Article 1701
Hulshof et al. Sample Size in Antipsychotics TrialsTABLE 1 | Characteristics of randomized placebo-controlled and head-to-head trials of antipsychotics in patients with dementia.











Antipsychotic versus placebo (33)
Auchus and Cheryl Bissey-
Black, 1997
Haloperidol AD Agitation OUTP 12 6 − − (non-commercial)
Howanitz and Wisotzek,
2001
Olanzapine VAS Diverse NPS NR 16 6 − (abstract) NR
Sugerman et al., 1964 Haloperidol CBS Psychosis HOS 18 6 − + (haloperidol)
Herz et al., 2002° Risperidone,
olanzapine
AD Agitation NR 29 6 − (abstract) NR
Hamilton and Bennet, 1962 Trifluoperazine CBS Psychosis HOS 27 8 − NR
Finkel et al., 1995 Thiothixene NR Agitation NH 35 11 − + (thiothixene)
Barnes et al., 1982 Loxapine,
thioridazine
NR Diverse NPS NH 60 8 − + (loxapine)
Petrie et al., 1982 Loxapine,
haloperidol
NR Diverse NPS HOS 63 8 − + (loxapine)
Paleacu et al., 2008 Quetiapine AD Diverse NPS NR 40 6 + + (quetiapine)
Rada and Kellner, 1976 Thiothixene CBS Diverse NPS HOS 63 4 − NR
Devanand et al., 1998 Haloperidol AD Diverse NPS OUTP 66 6 − − (non-commercial)
Ballard et al., 2005 Quetiapine AD Agitation NH 62 6 + + (commercial)#
Pollock et al., 2002 Perphenazine AD, VAS, and MIX Diverse NPS NH 54 2,5 − − (non-commercial)
Teri et al., 2000 Haloperidol AD Agitation HOS 70 16 + + (trazodone)
Street et al., 2000 Olanzapine AD Diverse NPS NH 206 6 + + (olanzapine)
Ballard et al., 2018 Pimavanserin AD Psychosis NH 181 12* + + (pimvaserin)
Tariot et al., 2006 Quetiapine,
haloperidol
AD Psychosis NH 284 10 + + (quetiapine)
Allain et al., 2000 Tiapride, haloperidol AD, VAS, and MIX Agitation NH-
HOS
306 3 + + (tiapride)
De Deyn et al., 2005 Aripiprazole AD Psychosis OUTP 208 10 − + (aripiprazole)
Zhong et al., 2007 Quetiapine AD and VAS Agitation NH 333 10 + + (quetiapine)
Schneider et al., 2006 Olanzapine,
quetiapine,
risperidone
AD Diverse NPS OUTP 421 12^ + + (olanzapine,
quetiapine,
risperidone)
De Deyn et al., 1999 Risperidone,
haloperidol
AD, VAS, and MIX Diverse NPS NH 344 12 + + (risperidone)
Satterlee et al., 1995° Olanzapine AD Diverse NPS NR 238 8 − + (olanzapine)
Mintzer et al., 2007 Aripiprazole AD Psychosis NH 487 10 − + (aripiprazole)
Streim et al., 2008 Aripiprazole AD Psychosis NH 265 10 − + (aripiprazole)
De Deyn et al., 2004 Olanzapine AD Psychosis NH-
HOS
652 10 + + (olanzapine)
Otsuka Ph, 2017a† Brexpiprazole AD Agitation NH 413 12 − (online) + (brexpiprazole)
Otsuka Ph, 2017b Brexpiprazole AD Agitation NH
−OUTP
270 12 − (online) + (brexpiprazole)
Deberdt et al., 2005 Olanzapine,
risperidone
AD, VAS, and MIX Psychosis NH
−OUTP
494 10 − + (olanzapine)
Katz et al., 1999 Risperidone AD, VAS, and MIX Diverse NPS NH 625 12 + + (risperidone)
Brodaty et al., 2003 Risperidone AD, VAS, and MIX Aggression NH 345 12 + + (risperidone)
Stotsky, 1984 Thioridazine NR Diverse NPS NH-
HOS
358 4 − NR
Mintzer et al., 2006 Risperidone AD Psychosis NH 473 8 + + (risperidone)
Head-to-head trials (18)
Vergara et al., 1980 Clomacran vs.
thioridazine
CBS Diverse NPS HOS 20 12 − + (clomacran)
Spagnolo et al., 1983 Clomacran,
thioridazine
VAS Diverse NPS HOS 30 3 − NR
Fontaine et al., 2003 Etoperidone,
thioridazine
NR Agitation NH 39 2 − + (olanzapine)
Carlyle et al., 1993 Olanzapine,
risperidone
AD, VAS, and MIX Aggression HOS 40 4 − NR
Garerl et al., 2004 Loxapine,
haloperidol
AD, VAS, and MIX Diverse NPS NR 60 8 − − (non-commercial)
(Continued)Frontiers in Pharmacology | www.frontiersin.org 5 February 2020 | Volume 10 | Article 1701
Hulshof et al. Sample Size in Antipsychotics Trialshomes, or hospitals. The target symptom for treatment consisted
of agitation, psychosis, or diverse NPSs.
Sample Size Variation and Calculations
Figure 2 shows the mean number of participants per
comparison group in each trial against publication year. The
symbols indicate the type of drug tested (conventional, atypical,
or both) and type of study (placebo-controlled or head-to-
head). In the conventional antipsychotic placebo-controlled
studies, the mean number per group was 34 patients (range
6–179), while those comparing atypical antipsychotics to
placebo included on average 107 patients per group (range 8–
237). The three trials that included both conventional and
atypical antipsychotics and compared these to placebo
included 104 patients per group (range 95–115). Head-to-
head trials included a mean number of 31 patients per group
(range 10–88). The increase in sample size over time seems to
be related to type of drug tested.
We calculated a reference sample size of 83 patients per group
for the placebo-controlled trials and 433 patients for the head-to-
head trials, as explained above. The group sample size was lower
than the reference sample size in 10 placebo-controlled trials of
conventional antipsychotics (small sample size) and higher in
one such trial (large sample size), whereas 5 of the 19 atypicalFrontiers in Pharmacology | www.frontiersin.org 6antipsychotic trials and none of the 3 trials including both
conventional and atypical antipsychotics had small sample
sizes. At least four of the five atypical underpowered
antipsychotic trials were investigator initiated, although one
was performed with commercially acquired funds. All head-to-
head trials had a small sample size that was lower than the
reference sample size of 433.
Sixteen of 47 articles (excluding 2 abstracts and 2 reports on
online trial registers) reported a sample size calculation (34%),
which was often called a power analysis (Table 1). Fourteen were
placebo-controlled trials and two head-to-head trials (Table 2).
Table 2 shows, which input for these sample size calculations
was reported. There were only three studies that reported
sufficient information (Ballard et al., 2005; Mintzer et al., 2006;
Schneider et al., 2006). Two studies reported an alpha that
differed from 5% (2.5% and 7%). Eight studies reported a beta
that differed from 20% and it varied between 1% and 15%. Except
for the alpha of 2.5%, this input will yield higher sample sizes.
Expected drop-out rates were reported in seven studies and
varied between 10% and 30%.
There were seven placebo-controlled trials that postulated an
expected treatment effect in terms of symptom reduction, four of
which reflected a relative symptom reduction below 20%. The
expected differences in relation to baseline means (relativeTABLE 1 | Continued











Morris and Rickels, 1984 Risperidone,
olanzapine,
promazine





Diverse NPS OUTP 56 6 − + (haloperidol)
Smith et al., 1974 Haloperidol,
thioridazine
CBS Psychosis NH 46 6 − NR
Götestam et al., 1981 Haloperidol,
thioridazine
(Pre)senile and VAS Diverse NPS HOS 47 8 − NR
Lovett et al., 1987 Cis(Z)−clopenthixol,
haloperidol
CBS Psychosis NH 54 6 − + (trifluoperazine)
Chan et al., 2001 Trifluoperazine,
haloperidol
AD, VAS, and MIX Diverse NPS OUTP
−HOS
58 12 − + (risperidone)




59 5 + NR
Ather et al., 1986 Olanzapine,
haloperidol
NR Diverse NPS NR 68 4 − + (chlormethiazole)
Sheng et al., 2004 Chlormethiazole,
thioridazine
AD and VAS Diverse NPS NR 60 8 − + (risperidone)
Rainer et al., 2007 Risperidone,
haloperidol
AD, VAS, MIX, FTD Diverse NPS OUTP 68 8 + + (quetiapine)
Mulsant et al., 2004 Quetiapine,
risperidone
AD, VAS and MIX Diverse NPS NH 86 6 − + (risperidone)
Sun et al., 2004 Risperidone,
olanzapine
DSM-IV dementia Diverse NPS HOS-
OUTP
116 8 − + (risperidone)
Gutzmann et al., 1997 Risperidone,
haloperidol
NR Restlessness HOS 176 4 − + (tiapride)February 2020 | VoAD stands for Alzheimer’s disease; CBS for chronic brain syndrome; HOS for hospital; MIX for mixed dementia (Alzheimer/vascular); NH for nursing home; NPS for neuropsychiatric
symptoms; OUTP for outpatients; Ph for Pharmaceutical company; NR for not reported; and VAS for vascular dementia.
° abstract only; * reduction in NPI Psychosis items at 12 weeks was the original primary outcome (clinicaltrials.gov); ^ discontinuation rate at week 36 was the primary outcome, but as it is
incomparable to other trials, we used response rate and reduction of symptoms at 12 weeks (see Table 3); † results of 0.5 mg group (n = 20) were not reported; # the term senile brain
disease was also used.lume 10 | Article 1701
Hulshof et al. Sample Size in Antipsychotics Trialssymptom reduction) were: 10% (Ballard et al., 2005); 11% (Tariot
et al., 2006); 12% (Brodaty et al., 2003); 14% (Street et al, 2000);
20% (Mintzer et al., 2006); 31% (De Deyn et al., 2004); 31%
(Ballard et al., 2018). For a head-to-head trial, the expected
relative risk reduction was 16% (Verhey et al., 2006).Frontiers in Pharmacology | www.frontiersin.org 7Reported Treatment Effects In Relation
To Sample Size
Table 3 presents the reported treatment effects in order of
sample size per study group. A positive difference in response
rate and negative difference in symptom reduction means thatFIGURE 2 | Scatter plot of sample sizes per arm over the years per treatment group.TABLE 2 | Input for sample size calculations*.
Study Alpha, % Beta, % Response rate or
mean symptom










Teri et al., 2000† 5 20 70% 30% 40% NR
Katz et al., 1999 5 20 50% 30% 20% NR
Street et al., 2000 5 20 NA NA −2.0 pts (NR) NR
Brodaty et al., 2003 5 20 NA NA −4.15 pts (NR) 30
De Deyn et al., 2004 5 15 NA NA −3.0 pts (NR) NR
Ballard et al., 2005 5 10 NA NA −6.0 pts (6) 25
Schneider et al., 2006 5 1^ 27%# 60%# −33%# NA#
Mintzer et al., 2006 5 5 45% 25% 20% 20
Zhong et al., 2007 2.5 20 NR NR NR 10
Paleacu et al., 2008 7 10 NR NR −25% pts (NR) NR
Ballard et al., 2018 5 10 NA NA −3.0 (6) 20
De Deyn et al., 1999 5 20 NR NR 20% 20
Allain et al., 2000 5 20 55% 30% 25% NR
Tariot et al., 2006 5 10 NA NA −4.5 (9) NR
Head-to-head trials
Verhey et al., 2006 5 10$ −14 pts −2.8 pts <−11.2 (NR) 25
Rainer et al., 2007 5 20 NR NR NR NRFebruary 2020 | Volume 10 |NA stands for not applicable, NR for not reported, pts for points (on instrument used to measure neuropsychiatric symptoms); * this table presents the 16 studies that reported a sample
size calculation (‘power analysis’) were included in this table; ¶ a difference in means needs to be accompanied by the population variance to calculate a sample size; † except for Teri et al.,
2000, all calculations were based on the comparison of the atypical antipsychotic group versus placebo; ^ beta was reported to be 20% for a difference in rates of -20%; # discontinuation
(not response) was the outcome; $ text also mentions 20%.Article 1701
Hulshof et al. Sample Size in Antipsychotics TrialsTABLE 3 | Results of randomized trials in order of group sample size.
Study Comparison groups N per
group


















Antipsychotic versus placebo (33)
Auchus and Cheryl
Bissey-Black, 1997
Haloperidol vs. placebo 6–6 — — — CMAI −1.0 (35.2); 5% .82
Howanitz and
Wisotzek, 2001
Olanzapine vs. placebo 8–8 — — — — — —
Sugerman et al.,
1964




−2.5 (nr); nr nr
Herz et al., 2002° Risperidone vs. placebo 14–8 — — — BPRS
Excitement
Nr (nr); nr ns .0001
Olanzapine vs. placebo 7–8 — — — Nr (nr); nr
Hamilton and
Bennet, 1962
Trifluoperazine vs. placebo 18–9 improvement on
psychiatric observation
22% nr MACC −0.7 (31.4); 2% ns
Finkel et al., 1995 Thiothixene vs. placebo 17–18 > 5 points on CMAI 51% nr CMAI −9.0 (30.5); 55% <.001


























Paleacu et al., 2008 Quetiapine vs. placebo 20–20 Improved on CGIC −5% ns NPI-NH −5.2 (41.0); 13% ns
Rada and Kellner,
1976



















Ballard et al., 2005 Quetiapine vs. placebo 31–31 — — — CMAI 3.5 (57.7); 8% .30
Pollock et al., 2002 Perphenazine vs. placebo 33–21 — — — NRS −4.9 (57.6); 9% .14
Teri et al., 2000 Haloperidol vs. placebo 34–36 improvement on ADCS-
CGIC$
1% 0.81 CMAI −1.3 (49.2*); 3% >.25
Street et al., 2000 Olanzapine 5 mg vs.
placebo
Olanzapine 10 mg vs.
placebo



























−0.5 (9.8); 5% .561































Deberdt et al., 2005 Aripiprazole vs. placebo 106–102 improvement on CGI-I 8% .18 NPI Psychosis −1.03 (12.4); 8% .017
Zhong et al., 2007 Quetiapine 100 mg vs.
placebo


















































Satterlee et al., 1995° Olanzapine vs. placebo 120–118 — — — BEHAVE-AD −0.4 (19.8); 2% ns
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Mintzer et al., 2007 Aripiprazole 2 mg vs.
placebo
Aripiprazole 5 mg vs.
placebo





















Streim et al., 2008 Aripiprazole vs. placebo 131–125 > = 50% decr NPI-NH 18% .006 NPI-NH
Psychosis
+0.1 (10.6); 1% ns
De Deyn et al., 2004 Olanzapine 1mg vs.
placebo
Olanzapine 2.5 mg vs.
placebo
Olanzapine 5 mg vs.
placebo



























Otsuka Ph, 2017a^ Brexpiprazole 1 mg vs.
placebo








Otsuka Ph, 2017b Brexpiprazole vs. placebo 133–137 — — — CMAI −2.4 (nr); nr .145














Katz et al., 1999 Risperidone 0.5 mg vs.
placebo
Risperidone 1 mg vs.
placebo



















Brodaty et al., 2003 Risperidone vs. placebo 173–172 improvement on CGI-I 22% < .001 CMAI
aggression
−4.4 (33.5); 23% <.001
Stotsky, 1984 Thioridazine vs. placebo 183–175 — — — Modified HAS −4.3 (nr); nr <.001
Mintzer et al., 2006 Risperidone vs. placebo 235–238 improvement on CGI-C 10% .019 BEHAVE-AD
Psychosis
−0.6 (7.9); 8% .118
Head-to-head trials (18)
Vergara et al., 1980 Clomacran vs. thioridazine 20 total Improvement on CGI 0% nr VTSRS nr (nr); nr ns
Spagnolo et al., 1983 Etoperidone vs.
thioridazine
15–15 clinical judgment 0% nr SHGRS nr (nr); nr nr
Fontaine et al., 2003 Olanzapine vs. risperidone 20–19 — (CGI-C was
administered)
nr ns NPI +8 (51.8); 15% ns
Carlyle et al., 1993 Loxapine vs. haloperidol 20–20 Any decrease in weekly #
of aggressive acts
15% nr weekly # of
aggressive acts
−1.1 (6.9); 16% ns
















Loxapine vs. thioridazine 21–20 global improvement nr nr BPRS +1.7 (63.6); 3% ns
Rosen, 1979 Haloperidol vs. thioridazine 24–18 — — — Modified BPRS +0.1 (3.2); 3% ns





25–22 improvement on CGI −6% nr GCGRS −4.1 (26.9); 15% <.05
Lovett et al., 1987 Trifluoperazine vs.
haloperidol
26–28 improvement on CGI 18% ns BPRS −1.2 (50.4); 2% ns
Chan et al., 2001 Risperidone vs.
haloperidol
29–29 — — — CMAI +2.0 (47.7); 4% ns
Verhey et al., 2006 Olanzapine vs. haloperidol 30–28 — (CGI was administered) — — CMAI +6.5 (70); 9% 0.338
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Six trials did not report what the effect of treatment on the
primary outcome was: four studies were old, published between
1974–1983, but two were relatively new, published after 2000
(Smith et al., 1974; Rada and Kellner, 1976; Vergara et al., 1980;
Spagnolo et al., 1983; Herz et al., 2002; Mulsant et al., 2004). Five
placebo-controlled studies reported only p-values without effect
sizes in the abstract (Katz et al., 1999; Brodaty et al., 2003;
Deberdt et al., 2005; Mintzer et al., 2006; Zhong et al., 2007).
Thirteen of 18 overpowered trials (72%) versus seven of 15
underpowered placebo-controlled trials (47%) yielded a
statistically significant difference between the study groups in
either response rate or symptom reduction. Two of 13 (15%)
and four of seven (57%) of these treatment effects respectively were
clinically relevant (difference in response rate > = 25%, or relative
symptom reduction > = 20%). The statistically significant response
rates were 10–22% and reported by studies with large sample sizes.
The two studies with a difference in response rate of > = 25%,
which is the difference deemed clinically relevant (Cohen, 2007),
were underpowered and did not report a statistically significant
result. In addition, large sample size trials reported statistically
significant relative symptom reductions between 10% and 23%,
and small sample size trials reported statistically significant relative
symptom reductions varying between 17% and 55%.
Many placebo-controlled trials had more than one
intervention group, adding up to a total of 54 individual
comparisons. Thirteen of the 33 overpowered comparisons
(39%) from 18 trials yielded a statistically significant treatment
effect on either response rate or symptom reduction, versus seven
of the 21 underpowered comparisons (33%) from 15 trials.
Five of 18 head-to-head trials reported a difference in
response rate of 10%, the lower limit that we set for non-Frontiers in Pharmacology | www.frontiersin.org 10inferiority in our reference sample size calculation, and four a
relative symptom reduction of 10%. Yet, none of these results
were statistically significant.
The reported treatment effect was lower than the expected
treatment effect in the 14 studies that presented an expected
treatment effect in a sample size calculation, except in two studies
(Street et al., 2000; Brodaty et al., 2003). The reported drop-out
rates varied between 6% and 37% (not shown), which was higher
than the expected drop-out rate in most studies.
Study Characteristics and Sample Size
Table 4 shows themean sample size per comparison group by type of
drug tested, trial duration, and type of funding. Themean sample size
per study group was statistically significantly higher in placebo-
controlled trials that tested an atypical antipsychotic drug (107.0)
or both a conventional and an atypical drug (103.8) in comparison to
placebo-controlled trials of conventional antipsychotics (34.4;
p < .05). The mean sample size per study group was also
statistically significantly higher in trials that lasted more than 6
weeks (109.2) compared to less than 6 weeks (28.9; p < .001), and
that were commercially (100.3) versus non-commercially (18.1;
p < .001) funded. Head-to-head-trials that tested atypical drugs
only had a significantly larger mean sample size (46.3) than trials
that tested conventional drugs (22.3; p < .05). Trial duration and
commercial funding did not seem to be related to the sample size of
head-to-head trials.DISCUSSION
We assessed the presence of large sample size fallacy in 51
antipsychotic trials in dementia. Most placebo-controlled trialsTABLE 3 | Continued
Study Comparison groups N per
group


















Ather et al., 1986 Chlormethiazole vs.
thioridazine
30–30 — — — CGBRS −1.9 (37.1); 5% nr
Sheng et al., 2004 Risperidone vs.
haloperidol
30–30 improvement on CGI 10% >.05 BEHAVE-AD 0 (15); 0% >.05
Rainer et al., 2007 Quetiapine vs. risperidone 36–32 improvement on CGI −3.4% nr NPI +2.2 (57.9); 4% ns
Mulsant et al., 2004 Risperidone vs. olanzapine 42–43 — — — NPI Nr (nr); nr ns
Sun et al., 2004 Risperidone vs.
haloperidol
57–59 > = 30% decrease on
BEHAVE-AD
1% nr BEHAVE-AD +0.1 (17.5); 1% ns
Gutzmann et al.,
1997
Tiapride vs. melperone 88–87 improvement on CGI 1% .675 restlessness −1.4 (56.2); 2% nsFebruary 2020 | Volume 10 | Artnr stands for not reported, ns means that the effect was reported as not statistically significant but no p-value was given; ADCS-CGIC stands for Alzheimer’s Disease Cooperative Study
Clinical Global Impression of Change; BEHAVE-AD for Behavioural pathology in Alzheimer’s disease scale; BPRS for Brief Psychiatric Rating Scale; CMAI for Cohen-Mansfield Agitation
Inventory; CGBRS for Crichton Geriatric Behavioral Rating Scale; GCGRS for Gottfires-Cronholm Geriatric Rating Scale; MACC for Motility affect communication cooperation behavioral
adjustment scale; NPI (-NH) for Neuropsychiatric Inventory (- Nursing Home version); NRS for Neurobehavioral Rating Scale; PANSS for Positive and Negative Syndrome Scale; SHGRS for
Stuard Hospital Geriatric Rating Scale; and VTSRS for Verdun Target Symptom Rating Scale.
° abstract only; * 49.2 is the weighted mean of baseline mean of all studies with CMAI total; ¶ reduction in NPI Psychosis at 12 weeks was originally the primary outcome (clinicaltrials.gov);
† Discontinuation rate at week 36 is primary outcome of trial, but as it is incomparable to other trials, we used response rate and reduction of symptoms at 12 weeks; ^ results of 0.5mg
group (n = 20) were not reported.icle 1701
Hulshof et al. Sample Size in Antipsychotics Trialsof conventional antipsychotics had small sample size, i.e. smaller
than the calculated reference sample size, but most trials of
atypical antipsychotics had large sample sizes. All head-to-head
trials had very small sample sizes. Only one third of trials
reported a sample size calculation. Thirteen of 18 trials with
large sample sizes (72%) reported a statistically significant
treatment effect, of which two (15%) were clinically relevant.
In contrast, seven of 15 placebo-controlled trials with small
sample sizes (47%) yielded a statistically significant treatment
effect, and four were clinically relevant (57%). None of the head-
to-head trials reported a statistically significant treatment effect,
even though some suggested non-inferiority.
Large Sample Size Fallacy
Sample sizes need to be large enough to guarantee a minimum
level of discriminative power to detect a real treatment effect.
Moreover, precision of an estimate increases with sample size.
Studies based on small sample size may yield a non-statistically
significant but clinically relevant treatment effect. On the
other hand, studies based on large sample size—larger than
necessary—may yield statistically significant but clinically
insignificant treatment effects (Roggla and Fortunat, 2004;
Chan et al., 2008). Large sample size fallacy occurs when such
results are interpreted as relevant for medical practice (Lantz,
2013; Lin et al., 2013). Nevertheless, pharmaceutical companies
and academic scholars benefit from statistically significant
treatment results being interpreted as clinically relevant
(Dickersin et al., 1992). The emphasis on statistical significance
was confirmed by six trials in our review that did not report effect
sizes, and five trials that reported just p-values in the abstract.
The sample sizes of trials testing atypical antipsychotics
versus placebo, whether or not simultaneously with a
conventional antipsychotic, were generally larger than
necessary. These trials were commercially funded by the
manufacturer of the atypical antipsychotic drugs. Only
investigator-initiated trials were too small. The majority of
large trials reported a statistically significant treatment effect,
despite lack of clinical relevance, which confirms the presence of
large sample size fallacy. The mean sample size was also higher
when the study lasted longer than 6 weeks and was commercially
funded, but this might be explained by the fact that placebo-
controlled trials of atypical antipsychotics were generally longer
and often industry-initiated. The chance of statistically
significant findings was further enhanced by the use ofFrontiers in Pharmacology | www.frontiersin.org 11multiple comparisons per study and multiple measurement
scales per outcome in a number of the larger trials.
Many placebo-controlled trials of conventional antipsychotics
had small sample sizes. Most were relatively old (published
before 1990) and seemed to be investigator-initiated. Some of
these trials reported clinically relevant results, but most were not
statistically significant. That small placebo-controlled trials
yielded statistically significant and clinically relevant effects
relatively often might reflect publication bias.
Head-to-head trials had sample sizes that were (much)
smaller than required, and these studies yielded non-
statistically significant results that sometimes suggested a
substantial effect. Even if we had set the limit for non-
inferiority at 15%, the required sample would have been a lot
higher than the sample sizes of the included studies were (346
without loss, and 385 with loss). It is unclear why these trials
were so clearly underpowered. Perhaps, industry has little to gain
from properly testing their own product against that of
competitors. Non-commercial funds might not be interested
in a trial with at least 2 × 433 patients to show that the
tested drugs are non-inferior, even if patients might be quite
willing to participate in a study that ensure treatment with an
active drug.
Sample Size Requirements
It is generally agreed that a trial protocol and report should
report a sample size calculation (CONSORT Group, 2010).
Nevertheless, only a third of trials in our review reported a
sample size calculation and just three were complete. Although
some trials can be considered old, most were published in the
1990s or later when it had become common to report trial
methods in detail. Sample size calculations are often not
(completely) reported in randomized trials in other fields of
research was well (Chan et al., 2008; Charles et al., 2009). One
review found that articles about newer randomized controlled
trials included sample size calculations more often, and showed
positive results more often (76%) than older studies (55%) (Latif
et al., 2011).
Some studies in our review reported a lower alpha (2.5%) or
beta (5%) than is usual in sample size calculations (5% and 20%
respectively). In addition, the MCID proposed in the sample size
calculations seemed rather small: difference in response rates
<25% in 3/6 trials, and in relative risk reduction of <20% in 4/7
trials. The lower the alpha, beta, and MCID, the higher theTABLE 4 | Mean sample size by study characteristic.
Study characteristic Placebo-controlled trials Head-to-head trials
n Mean (SD) n Mean (SD)
Type of drug Conventional antipsychotic (ref) 11 34.4 (48.8) 9 22.3 (7.1)
Atypical antipsychotic 19 107.0 (60.5)^ 4 46.3 (29.5)^
Conventional and atypical antipsychotic 3 103.8 (94.7)^ 3 33.3 (14.4)
Trial duration = < 6 weeks (ref) 11 28.9 (4.4) 10 32.7 (21.0)
> 6 weeks 22 109.2 (12.6)* 8 28.2 (14.2)
Type of funding Non-commercial (ref) 7 18.1 (9.6) 5 21.6 (5.4)
Commercial 24 100.3 (57.5)* 13 34.2 (20.0)February 2020 | Volume 10 |^p < .05 compared to reference group; *p < .001 compared to reference group.Article 1701
Hulshof et al. Sample Size in Antipsychotics Trialscalculated sample size will be and hence the power to detect a
statistically significant but not clinically relevant treatment effect.
Moreover, even if the expected difference is equal to the MCID, a
proportion of the patients will not have a clinically relevant effect
on the individual level. On the other hand, the expected drop-out
rate in the sample size calculations was mostly lower than the
(mean) reported drop-out, and this would have led to a
spuriously smaller calculated sample size. Real drop-out might
have been high because trial duration was long on average. Most
trials lasted more than a month, even though in clinical practice,
antipsychotics usually show an effect within 2 weeks, four at the
most. It has been estimated that up to 64% of trials with
continuous outcomes are underpowered or overpowered
because of imprecise input (Tavernier and Giraudeau, 2015).
Strengths and Limitations
To our knowledge determinants of sample size in trials testing
antipsychotics for NPSs in dementia have not been studied
previously. Our study showed that sample size calculations in
the reports of these trials were missing on a large scale as was the
correct interpretation of effect size. A limitation of our study is its
focus on antipsychotic trials in dementia, which might be
perceived as a small field of research. In addition, the
interpretation of our results is limited by the possible presence
of multiple testing. Many trials used multiple comparisons of
either different drugs, different dosages, multiple outcomes, and
sometimes multiple measurement instruments per outcome.
Such multiple testing might reinforce the large sample
size fallacy.
With our study, we do not want to suggest that large sample
sizes should be avoided. It is important for clinical practice that
study results are precise. Moreover, large sample sizes are very
useful for identification of adverse effects. Small trials should not
be avoided either, as long as they are published irrespective of
results and available for pooling in meta-analyses.Frontiers in Pharmacology | www.frontiersin.org 12The implication of our study is that researchers need to be
encouraged to report and consider effect sizes in line with p-
values to avoid the large sample size fallacy. Journals should
probably mention this in their author instructions.CONCLUSION
Placebo-controlled trials that tested atypical antipsychotics
showed large sample size fallacy. Placebo-controlled trials of
conventional antipsychotics and head-to-head trials had
insufficient power to detect a real difference between the
treatment groups. Sample size calculations in antipsychotic
trials for dementia need to be reported adequately.DATA AVAILABILITY STATEMENT
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